Saccharomyces boulardii for the treatment of Clostridium difficile-associated colitis.
S. boulardii has been investigated in Europe and the US, and preliminary reports indicate that it is safe and effective in conjunction with vancomycin or metronidazole for the treatment of CDC, predominantly in patients who develop recurrence. S. boulardii in combination with vancomycin or metronidazole has not been shown to be more effective than either of these agents alone for treatment of a first episode of CDC. In addition, S. boulardii has not been studied in immunocompromised patients who may be at risk for developing fungemia. Ultimately, large-scale clinical studies are necessary to determine whether S. boulardii should be routinely used to treat patients with recurrent CDC. S. boulardii is currently undergoing Phase III clinical trials for CDC treatment in the US. Clinicians interested in information regarding participation in current studies may contact Biocodex Inc., in Seattle, Washington.
Eddy
J T
JT
School of Pharmacy, West Virginia University, Morgantown 26506, USA.
Stamatakis
M K
MK
Makela
E H
EH
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000994:Antitrichomonal Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D016360:Clostridioides difficile; D004359:Drug Therapy, Combination; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology / Q000382:microbiology* / Q000628:therapy*; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D012307:Risk Factors; D012440:Saccharomyces; D014640:Vancomycin / Q000627:therapeutic use; D015002:Yeast, Dried / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000994:Antitrichomonal Agents; D008795:Metronidazole; D014640:Vancomycin